The UK’s uncompetitive policies have led to years of chronic underinvestment
Copy link
NHS pricing row has made Britain unattractive, says drugs giant
The UK’s uncompetitive policies have led to years of chronic underinvestment
465 words~2 min read
Related reading
NHS risks missing out on new drugs, warns Mounjaro maker
Eli Lilly calls on Britain’s health service to pay higher prices for medicines
‘Patients will suffer’: tales from the frontline of the UK pharma crisis
The pricing standoff between government and industry has stalled research and put thousands of jobs at risk
Britain is ‘a terrible place’ to sell medicines, says drug firm executive
Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments
UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker
Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more
Mounjaro manufacturer blasts UK as ‘worst country in Europe’ for drug prices
The boss of Eli Lilly, Dave Ricks, warns that Britain will miss out on new drugs as a result of pricing issues
AstraZeneca threatens to stop investing in Britain
Drug company chairman calls for change to ‘appalling’ rules on NHS drug prices